Latest News

19 May 2017

FDA CBER Biennial Audit

Posted by Maxim Biomedical, Inc.

Maxim Biomedical has completed our FDA CBER Biennial Audit and is happy to announce our team received zero observations. Our team worked with FDA during the week-long audit to ensure our quality system and products were meeting all FDA cGMP regulations. Congratulations to our auditing team members and to each Maxim personnel involved with the audit. Great job everyone!

02 August 2016

Maxim exhibits at the 2016 AACC Conference

Posted by Maxim Biomedical, Inc.

Maxim Biomedical was pleased to be among the thousands of exhibitors and attendees at this year 2016 AACC Conference in Philadelphia, PA between 08/02/16 – 08/04/16. Thank you for your positive feedback on our newest prototype LAg LFI Kit and Reader which we unveiled at this year’s conference. See below for our 2016 AACC flyers:
· 2016 AACC – Antigens & Antibodies·
· 2016 AACC – LAg-Avidity LFI for HIV-1 Incidence
· 2016 AACC – CMO/CRO Services Customized for You

01 June 2015

2015 Conference on Retroviruses and Opportunistic Infections (CROI)

Posted by Maxim Biomedical, Inc.

Maxim Biomedical was mentioned at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI). See the abstract and poster presented!

 

 

10-15 April 2015

Our 2 year audit for FDA

Posted by Maxim Biomedical, Inc.

Our 2 year audit for FDA cGMP was performed and approved by FDA.

 

 

 

26 January 2015

Annual Renew Audit for ISO 13485:2003

Posted by Maxim Biomedical, Inc.

Our annual renew audit for ISO 13485:2003 was performed and approved by G-MED.

 

 

30 August 2015

CDC approval for HIV-1 LAg-Avidity DBS and Serum/Plasma EIA Kits

Posted by Maxim Biomedical, Inc.

Maxim Biomedical, Inc. becomes the first company in the nation to be CDC approved for HIV-1 LAg-Avidity DBS and Serum/Plasma EIA Kits.